This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer
by Zacks Equity Research
Merck and Daiichi's raludotatug deruxtecan wins FDA Breakthrough tag for treating CDH6 expressing platinum-resistant ovarian, primary peritoneal or fallopian tube cancers.
OLMA Stock Soars 47% in September So Far on Second PFE Deal
by Zacks Equity Research
Olema Pharmaceuticals surges 47% in September after striking a second collaboration with Pfizer for its lead breast cancer product candidate, palazestrant.
Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects
by Kinjel Shah
Pfizer's late-stage pipeline, from oncology blockbusters to mRNA vaccines, positions it for long-term growth despite recent setbacks.
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
by Ekta Bagri
Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.
The Zacks Analyst Blog Highlights Oracle, AstraZeneca, Shopify and Blue Ridge Bankshares
by Zacks Equity Research
Oracle, AstraZeneca, Shopify, and Blue Ridge Bankshares show strong growth and strategic market opportunities.
Top Research Reports for Oracle, AstraZeneca & Shopify
by Mark Vickery
Oracle's cloud boom, AstraZeneca's drug pipeline, and Shopify's AI tools headline fresh analyst reports on major stocks.
J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum
by Kinjel Shah
J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.
LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal
by Zacks Equity Research
Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.
Will LLY's Oncology Portfolio Provide Key Diversification Benefits?
by Ahan Chakraborty
Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
by Ekta Bagri
Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.
Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?
by Zacks Equity Research
Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.
IonQ Sets Bold Quantum Goal but High Valuation Makes Investors Wary
by Urmimala Biswas
IonQ's quantum roadmap targets 800 logical qubits by 2027 and 80,000 by 2030 but lofty valuation keeps investors cautious.
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
by Zacks Equity Research
Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.
MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline
by Kanishka Das
Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.
J&J Gears Up for Some Key New Drug Approvals and Launches
by Kinjel Shah
JNJ believes 10 of its new products and pipeline candidates can deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta and others.
MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate
by Zacks Equity Research
Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.
Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?
by Kanishka Das
Merck halts Gardasil shipments in China after weak demand hurts sales, with declines also seen in Japan.
Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now?
by Urmimala Biswas
BFLY trades at distressed levels with analyst targets signaling sharp upside, while TEM's premium valuation tempers its appeal.
ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth
by Kinjel Shah
AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer
by Zacks Equity Research
Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung cancer.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Strategic Partnerships Power Tempus AI's Healthcare Expansion
by Sridatri Sarkar
TEM deepens collaborations in oncology and neuroscience using its Lens and Next platforms to accelerate precision medicine.